Table 4.
Results of conditional exact logistic regression analysis: risk of first- and second-dose AEFIs associated with Parkinson’s Disease and Multiple Sclerosis diagnosis. All estimates controlled for pairing factors (sex, age, comorbidities, allergies) and type of vaccine received (Gam-COVID-Vac or Pfizer-BioNTech).
| Any AEFI | Systemic AEFIs | Local AEFIs | |
|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| First dose | |||
| Neurological diseases | |||
| No | 1.00 | 1.00 | 1.00 |
| Parkinson’s Disease | 0.40 (0.11–1.19) | 0.62 (0.16–2.12) | 0.36 (0.09–1.20) |
| Multiple Sclerosis | 0.41 (0.08–1.62) | 1.30 (0.43–4.09) | 0.42 (0.13–1.17) |
| Second dose | |||
| Neurological diseases | |||
| No | 1.00 | 1.00 | 1.00 |
| Parkinson’s Disease | 0.19 * (0.03–0.66) | 0.42 (0.12–1.29) | 0.12 * (0.01–0.51) |
| Multiple Sclerosis | 0.73 (0.15–3.42) | 0.66 (0.20–2.05) | 0.95 (0.28–3.17) |
Notes: OR, odds ratio; CI, confidence interval. * statistically significant (p < 0.05).